加载中
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
前收盘价
US$3.90
−US$0.07 · -1.76%
盘中时间采用ET。市场数据可能有所延迟。
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
日内区间
当前US$3.90
52周区间
当前US$3.90
盘中时间采用ET。市场数据可能有所延迟。
Adial Pharmaceuticals, Inc. is a biopharmaceutical enterprise operating at the clinical stage, dedicated to researching and developing innovative therapeutic options for the management and prevention of addiction and associated disorders. Its primary investigational compound, AD04, functions as a selective serotonin-3 antagonist and is currently undergoing pivotal Phase III clinical trials for the treatment of alcohol use disorder. Beyond this flagship product, the company is also exploring drug candidates aimed at providing non-opioid pain relief and addressing a range of other medical conditions. Established in 2010, Adial Pharmaceuticals, Inc. is headquartered in Charlottesville, Virginia.
日内区间
当前US$3.90
52周区间
当前US$3.90
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | 564 USD | — | — |
| 毛利 | — | — | −564 USD | — | — |
| 研究与开发 | 261.97万 USD | 322.92万 USD | 126.71万 USD | 195.03万 USD | 839.56万 USD |
| 销售、一般及管理费用 | 517.98万 USD | 505.52万 USD | 562.09万 USD | 890.92万 USD | 934.47万 USD |
| 营业费用 | 779.95万 USD | 828.45万 USD | 688.74万 USD | 1085.95万 USD | 1928.87万 USD |
| 利息收入 | 14.96万 USD | 17.87万 USD | 6.98万 USD | 6.33万 USD | 6539 USD |
| 折旧和摊销 | 565 USD | 565 USD | 564 USD | 564 USD | 5.51万 USD |
| 营业利润 | −779.95万 USD | −828.45万 USD | −688.79万 USD | −1085.95万 USD | −1928.87万 USD |
| 净利润 | −797.72万 USD | −1319.75万 USD | −700.19万 USD | −1273.14万 USD | −1942.33万 USD |
公司数据更新于 2026年10月11日。
已公布业绩及可用的市场共识预期。
已公布业绩及可用的市场共识预期。
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
